Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PYGB | P11216 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CD69 | Q07108 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8343760 | 0.82 | LGALS3 (0.39) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL11199589 | 0.81 | MAPK1 (0.41) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL143296 | 0.81 | MAPK1 (0.41) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL564385 | 0.81 | MAPK1 (0.41) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL16026724 | 0.81 | MAPK1 (0.41) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL5664392 | 0.80 | LGALS1 (0.37) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL3269920 | 0.79 | PYGB (0.43) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL767424 | 0.79 | PYGB (0.43) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL1985946 | 0.79 | PYGB (0.43) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL6157450 | 0.79 | PYGB (0.43) | LGALS3LGALS1LGALS9LGALS8MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611286-B2 | Ruthenium carbon monoxide releasing molecules and uses thereof | ALFAMA, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-2734235-B1 | RUTHENIUM CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF | ALFAMA INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160237105-A9 | RUTHENIUM CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF | ALFAMA, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20150322105-A1 | RUTHENIUM CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF | ALFAMA, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| US-9062089-B2 | Ruthenium carbon monoxide releasing molecules and uses thereof | ALFAMA, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140219996-A1 | RUTHENIUM CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF | ALFAMA- Investigacao e Desenvolvimento de Produtos Farmacêuticos, Lda. (PT) | 2014-08-07 | — | — | US | disclosed |
| EP-2734235-A1 | RUTHENIUM CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF | Alfama, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013013179-A1 | RUTHENIUM CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF | ALFAMA, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-0506963-A1 | PRODUCTION OF HUMAN BASIC FGF MUTEIN | Takeda Chemical Industries, Ltd. (JP) | 1992-10-07 | — | — | EP | disclosed |
| WO-1991009126-A1 | PRODUCTION OF HUMAN BASIC FGF MUTEIN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237105-A9 | RUTHENIUM CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF | CHRM1, CHRM2, CHRM3 | LGALS3 2285/4885LGALS1 1454/4885LGALS9 2929/4885 |
| US-20140219996-A1 | RUTHENIUM CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF | CHRM1, CHRM2, CHRM3 | LGALS3 1311/4885LGALS1 738/4885LGALS9 1822/4885 |
| US-20150322105-A1 | RUTHENIUM CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF | CHRM1, CHRM2, CHRM3 | LGALS3 2285/4885LGALS1 1454/4885LGALS9 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.